Os therapies forms subsidiary os animal health to commercialize ost-her2 for canine osteosarcoma

New york--(business wire)--os therapies (nyse-a: ostx) (“os therapies” or “the company”), a clinical-stage immunotherapy and antibody drug conjugate (adc) biopharmaceutical company, today announced the launch of os animal health, inc., a wholly owned subsidiary focused on commercializing ost-her2 for the treatment of canine osteosarcoma. ost-her2 market opportunity in canine osteosarcoma exceeds $150 million recent data in prevention of amputation in frontline canine osteosarcoma and control of.
OST Ratings Summary
OST Quant Ranking